KellBenx Licenses Interleukin Biomarkers from Cedars-Sinai | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biotech startup KellBenx announced on Monday a licensing agreement with Cedars-Sinai Medical Center in Los Angeles for three interleukin biomarkers for the development of a blood-based test to predict premature births.

According to the KellBenx, the agreement is the first step to the possible development of a minimally invasive test that can predict preterm delivery early in pregnancy or even before a woman becomes pregnant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.